View from City Road: Fisons running out of puff
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Patrick Egan has slashed away at Fisons until all that is left is a high-quality drugs and scientific instruments business. Or so he says. In fact he has slashed away at the dross and uncovered very little of any worth at all.
Putting scientific instruments to one side - sadly, the best place for them - Fisons is left with little more than a few relatively old asthma drugs, with profit margins half the industry average, and a leadership expertise in inhalers.
Admittedly asthma is a growing problem. Exploited cannily, the drugs could be more profitable than they are. But others are catching up fast with new asthma products, and Fisons' expertise looks less unique by the day.
Mr Egan complains that the City is undervaluing Fisons. But the fact that he cannot find anyone suitable to take on the role of chief executive suggests his industry peers agree.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments